2023 World Conference on Lung Cancer (Posters)-EP12.01. A Real World Cohort Study of First Line Afatinib in Patients with EGFR mutant Advanced Non Small Cell Lung Cancer in Vietnam

EP12.01. A Real World Cohort Study of First Line Afatinib in Patients with EGFR mutant Advanced Non Small Cell Lung Cancer in Vietnam - PDF(Slides)

Back to course

Pdf Summary

A multi-center study was conducted in Vietnam to evaluate the effectiveness and tolerability of first-line afatinib in patients with advanced non-small cell lung cancer (NSCLC) with EGFR mutations. The study included a total of 343 patients from 9 Oncology centers who were treated with afatinib between April 2018 and June 2022.<br /><br />The study found that the median time to treatment failure (TTF) was 16.7 months, and the median overall survival was not reached with a median follow-up time of 26.3 months. The TTF was longer in patients with the common EGFR mutation subgroup (Del19 and L858R) compared to the uncommon mutation subgroup. There were no significant differences in TTF based on the starting dose of afatinib.<br /><br />The study also analyzed the safety profile of afatinib and found that diarrhea, rash, paronychia, stomatitis, and dry skin were the most common treatment-related adverse events. Grade 3 adverse events were observed in a small percentage of patients.<br /><br />The objective response rate (ORR) was high in patients with the common EGFR mutations, with an ORR of 82.6% in patients with Del19 mutations and 73.3% in patients with L858R mutations.<br /><br />Overall, the study confirmed the effectiveness and tolerability of first-line afatinib in Vietnamese patients with EGFR mutant advanced NSCLC. The study emphasized the importance of individualized dosing and proactive management of adverse events to optimize treatment outcomes.<br /><br />However, the study acknowledged the limitations of being a retrospective study and called for further research and studies in this field.

Asset Subtitle

Phuong Pham

Meta Tag

Speaker Phuong Pham

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

Vietnam

multi-center study

afatinib

non-small cell lung cancer

NSCLC

EGFR mutations

treatment failure

overall survival

safety profile

adverse events